公开(公告)号：US08859492B2

公开(公告)日：2014-10-14

申请号：US13470299

申请日：2012-05-12

申请人： James A. Cowan ,  Ada S. Cowan ,  Donna T. Palmer

发明人： James A. Cowan ,  Ada S. Cowan ,  Donna T. Palmer

IPC分类号： C07K19/00 ,  C07K7/08 ,  C07K14/46 ,  C07K2/00 ,  A61K38/05 ,  A61K38/10 ,  A61K38/17 ,  A61K38/08 ,  A61P31/00 ,  C07K5/068 ,  C07K1/113 ,  A61K47/48 ,  C07K7/06 ,  C07K5/02 ,  C07H23/00 ,  A61K38/00

CPC分类号： C07K14/825 ,  A61K31/424 ,  A61K38/00 ,  A61K38/10 ,  A61K38/16 ,  A61K47/547 ,  C07F17/02 ,  C07H21/00 ,  C07H23/00 ,  C07K5/022 ,  C07K7/06 ,  C07K2319/20 ,  C07K2319/70

摘要： It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.

摘要翻译： 本发明的目的是通过将这些分子连接到金属结合部分来提供与具有低亲和力的靶（以下称为“配体部分”）结合的分子的改善的药理学性质，由此产生组合分子 通常称为“金属药物”或“金属治疗剂”。金属药物的金属结合结构域通常催化氧化还原酶化学或作为路易斯酸催化剂，从而导致由于结合而接近的蛋白质和核酸的修饰 的配体部分。

公开(公告)号：US20120289454A1

公开(公告)日：2012-11-15

申请号：US13470299

申请日：2012-05-12

申请人： James A. Cowan ,  Ada S. Cowan ,  Donna T. Palmer

发明人： James A. Cowan ,  Ada S. Cowan ,  Donna T. Palmer

IPC分类号： C07K19/00 ,  C07K7/08 ,  C07K14/46 ,  C07H23/00 ,  C07K2/00 ,  C07H1/00 ,  C12N9/99 ,  A61K38/05 ,  A61K38/10 ,  A61K38/17 ,  A61K38/08 ,  A61P31/00 ,  C07K5/068 ,  C07K1/113

CPC分类号： C07K14/825 ,  A61K31/424 ,  A61K38/00 ,  A61K38/10 ,  A61K38/16 ,  A61K47/547 ,  C07F17/02 ,  C07H21/00 ,  C07H23/00 ,  C07K5/022 ,  C07K7/06 ,  C07K2319/20 ,  C07K2319/70

摘要： It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.

摘要翻译： 本发明的一个目的是通过将这些分子连接到金属结合部分来提供与具有低亲和力的靶（以下称为配体部分）结合的分子的改进的药理学性质，由此产生通常称为的组合分子 作为金属药物或金属治疗剂。 金属药物的金属结合结构域通常催化氧化还原酶化学或用作路易斯酸催化剂，导致由于配体部分与其靶标的结合而非常接近的蛋白质和核酸的修饰。

公开(公告)号：US07141542B2

公开(公告)日：2006-11-28

申请号：US10020799

申请日：2001-11-30

申请人： Siu Man L. Cowan ,  Vincent McGinniss ,  Donna T. Palmer ,  Steven M. Risser ,  Richard S. Brody

发明人： Siu Man L. Cowan ,  Vincent McGinniss ,  Donna T. Palmer ,  Steven M. Risser ,  Richard S. Brody

IPC分类号： A61K38/00 ,  A61K38/28 ,  A61K31/715

CPC分类号： A61K9/0078 ,  A61K9/0073 ,  A61K38/28 ,  A61K47/10 ,  A61K47/26

摘要： The invention is directed to a stable formulation of a biologically active protein useful for aerosol delivery to the respiratory tract of a patient in need of treatment comprising: (a) a carrier liquid comprising from about 10% to from about 100% V/V water and from about 0% to from about 90% V/V of an organic liquid; (b) a biologically effective amount of a protein suspended or dissolved in a carrier liquid; and (c) a stabilizing effective amount of a derivatized carbohydrate stabilizing agent suspended or dissolved in said carrier liquid. The stable formulations of the invention may optionally contain about 0.1% to about 5.0% W/V of a pharmaceutically acceptable excipient.